Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsHenry Schein Inc (HSIC)
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.11
+0.27%
HEALTHCARE · Cap: $5.52M
HSIC
Henry Schein Inc
$86.38
-0.70%
HEALTHCARE · Cap: $9.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Henry Schein Inc generates 101154% more annual revenue ($13.60B vs $13.43M). HSIC leads profitability with a 3.0% profit margin vs -8.5%. HSIC earns a higher WallStSmart Score of 53/100 (C-).
HKPD
Avoid29
out of 100
Grade: F
HSIC
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HKPD.
Margin of Safety
+47.4%
Fair Value
$155.18
Current Price
$86.38
$68.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.2% — below average capital efficiency
Revenue declined 31.7%
Expensive relative to growth rate
Moderate valuation
3.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HKPD
The strongest argument for HKPD centers on Price/Book, Altman Z-Score, Debt/Equity.
Bull Case : HSIC
HSIC has a balanced fundamental profile.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : HSIC
The primary concerns for HSIC are PEG Ratio, P/E Ratio, Profit Margin. Thin 3.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
HKPD profiles as a turnaround stock while HSIC is a value play — different risk/reward profiles.
HSIC is growing revenue faster at 6.7% — sustainability is the question.
HSIC generates stronger free cash flow (196M), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HSIC scores higher overall (53/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.
Henry Schein Inc
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?